Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 113 - 120 of 12140 results
DOJ Antitrust Implements Whistleblower Incentive
July 15, 2025| Blog| Viewpoint
Amenities Draw Law Firm Mintz’s S.F. Office to 525 Market St.
July 15, 2025| News
Is Your Enantiomer Possessed?
July 15, 2025| Blog| Viewpoint
MintzTech Connect Industry News: Spotlight on Coworker.ai
July 15, 2025| Article| Viewpoint
MintzTech Connect: All Things Technology — July 2025
July 15, 2025| Article| Viewpoint
401K Cybersecurity Compliance Creates These New ERISA Duties
July 15, 2025| News
Deepfakes Face Deep Trouble: Revenge Porn in the Workplace
July 14, 2025| Blog| Viewpoint
New Jersey Adopts QSBS Exclusion: A Game-Changer for In-State Investors and Founders
July 14, 2025| Alert| Viewpoint
News & Press Releases
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Mintz Advises the Placement Agents in CAMP4’s up to $100 Million Private Placement
September 12, 2025
Mintz advised the placement agents in connection with CAMP4's up to $100 million private placement. The private placement included upfront gross proceeds of $50 million in exchange for common stock (and pre-funded warrants in lieu of common stock for certain investors). In addition, CAMP4 will be eligible to receive up to an additional $50 million in gross proceeds in exchange for common stock (and pre-funded warrants for certain investors), subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a Phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01.
Events
Podcasts
Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|